Erasca (ERAS) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Erasca (ERAS) right now is RAS/MAPK is a large, underserved target: RAS mutations drive a meaningful share of lung, pancreatic, and colorectal cancers and have long been considered difficult to drug. Product revenue is ~$0 (no approved products). If that keeps playing out, the setup is favourable; the risk to it is erasca is pre-revenue and unprofitable, so its value depends on clinical trials that can fail at any phase, and single disappointing readouts can move the stock sharply. No one can predict where ERAS trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Erasca (ERAS) higher?
1. RAS/MAPK is a large, underserved target
RAS mutations drive a meaningful share of lung, pancreatic, and colorectal cancers and have long been considered difficult to drug. If Erasca's pan-RAS and pan-KRAS approaches work across multiple mutation types, the addressable population is large. That breadth is the core of the bull thesis.
2. Early ERAS-0015 data and registration plans
Preliminary Phase 1 dose-escalation data for the pan-RAS molecular glue ERAS-0015 showed responses in KRAS G12X lung and pancreatic cancer with a generally favorable safety profile. Management has outlined potentially registration-enabling trials starting in 2027, which would mark a step from early signals toward pivotal data.
3. Extended cash runway
After a July 2026 offering of roughly $550 million on top of prior cash, Erasca projects runway well beyond 2028. A multi-year cushion reduces near-term financing risk and lets the company fund several trials, though the raises add to share count and dilute existing owners.
4. Sharpened pipeline focus
Discontinuing naporafenib and terminating the Novartis license concentrated spend on ERAS-0015 and ERAS-4001. A tighter pipeline can improve capital efficiency, but it also raises the stakes on the remaining programs since there are fewer shots on goal.
What could weigh on ERAS?
Erasca is pre-revenue and unprofitable, so its value depends on clinical trials that can fail at any phase, and single disappointing readouts can move the stock sharply. Early Phase 1 response data are preliminary, involve small patient numbers, and may not hold up in larger, controlled studies. The company competes directly with better-financed RAS programs, most notably Revolution Medicines, whose daraxonrasib has shown strong pancreatic-cancer survival data. Ongoing losses mean further dilutive equity raises are likely, and the multi-billion-dollar market cap already assumes substantial clinical and commercial success that is far from guaranteed.
Where ERAS trades today
A forecast starts from where the stock actually is. These are ERAS's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for ERAS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a ERAS forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ERAS guide and whether ERAS is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ERAS outlook
The bottom line: what is driving Erasca (ERAS) is RAS/MAPK is a large, underserved target, with product revenue at ~$0 (no approved products). If that keeps playing out the setup is favourable; the risk is erasca is pre-revenue and unprofitable, so its value depends on clinical trials that can fail at any phase, and single disappointing readouts can move the stock sharply. No one can predict the price, so treat any ERAS forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ERAS with Walnut
Use Erasca as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Erasca (ERAS)?
+
No one can reliably predict where ERAS will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Erasca higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ERAS higher?
+
The main growth drivers are RAS/MAPK is a large, underserved target; Early ERAS-0015 data and registration plans; Extended cash runway. Whether they play out is the real question, not a guaranteed path.
What are the risks to ERAS?
+
Erasca is pre-revenue and unprofitable, so its value depends on clinical trials that can fail at any phase, and single disappointing readouts can move the stock sharply. Early Phase 1 response data are preliminary, involve small patient numbers, and may not hold up in larger, controlled studies. The company competes directly with better-financed RAS programs, most notably Revolution Medicines, whose daraxonrasib has shown strong pancreatic-cancer survival data. Ongoing losses mean further dilutive equity raises are likely, and the multi-billion-dollar market cap already assumes substantial clinical and commercial success that is far from guaranteed.
Will ERAS stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Erasca's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ERAS a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ERAS "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.